Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?

This article compares FBT (First Trust Nasdaq Biotech ETF) and IBB (iShares Nasdaq Biotechnology ETF) across three structural dimensions: cost, composition, and recent performance. The analysis reveals that FBT's narrower 30-stock portfolio strategy generated significantly higher returns (53.2% YoY) relative to its broader competitor, illustrating the performance variance between concentrated and diversified exposure within the biotech sector.

The trade-off between concentration and diversification becomes material at the fee level. FBT's 11-basis-point expense ratio, though not extreme, combined with its concentrated holdings in fewer positions, introduces elevated idiosyncratic risk relative to a more diversified fund structure. This structure amplifies both upside and downside volatility, particularly sensitive to single-name developments or clinical trial outcomes affecting portfolio constituents like AMGN and GILD.

The comparison is primarily instructional rather than prescriptive—highlighting how ETF mechanics (holdings count, weighting methodology, fee structure) interact with recent biotech sector momentum. Both funds remain correlated with underlying biotech fundamentals (pipeline progress, regulatory decisions, capital allocation), but FBT's concentration creates directional sensitivity asymmetry compared to IBB's broader index methodology.

Sector implication: The biotech sector's recent outperformance has widened the performance gap between concentrated and diversified strategies. This structural divergence may persist as long as select mega-cap names and clinical successes dominate sector returns, but concentration risk remains an embedded portfolio consideration for selective exposure strategies.